Omigapil
- Generic Name
- Omigapil
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17NO
- CAS Number
- 181296-84-4
- Unique Ingredient Identifier
- 5V14HD0N4Q
- Background
Omigapil has been used in trials studying the treatment of Congenital Muscular Dystrophy.
Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Santhera Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT01805024
- Locations
- 🇺🇸
NINDS, Bethesda, Maryland, United States
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)
Phase 2
Completed
- Conditions
- Amyotrophic Lateral Sclerosis
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 350
- Registration Number
- NCT00230074
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 2
Completed
- Conditions
- Amyotrophic Lateral Sclerosis
- First Posted Date
- 2003-11-11
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 551
- Registration Number
- NCT00072709
- Locations
- 🇺🇸
Novartis USA, East Hanover, New Jersey, United States
🇧🇪Novartis Belgium, Vilvoorde, Belgium
🇨🇭Novartis Switzerland, Bern, Switzerland
A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis
Phase 2
Completed
- Conditions
- Amyotrophic Lateral Sclerosis
- First Posted Date
- 2002-05-10
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT00036413
- Locations
- 🇺🇸
Neurological Institute, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath